GS-248 is under clinical development by Gesynta Pharma and currently in Phase II for Raynauds Disease. According to GlobalData, Phase II drugs for Raynauds Disease have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how GS-248’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

GS-248 overview

GS-248 (OX-MPI) is under development for the treatment of Raynaud's disease (microvascular disease), systemic sclerosis and endometriosis. It is microsomal prostaglandin E synthase-1 (mPGES-1) inhibitor. It is administered through the oral route.

Gesynta Pharma overview

Gesynta Pharma (Gesynta) is a biopharmaceutical company that develops drugs for the treatment of microvascular disease in chronic inflammatory conditions. It specializes in arachidonic acid research to analyze anti-inflammatory and vasoprotective effects in cardiovascular diseases and cancer. Gesynta is headquartered in Solna, Stockholm, Sweden.

For a complete picture of GS-248’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.